Orion Corporation's Recent Share Conversion Announcement
On a recent occasion, Orion Corporation, a prominent player in the pharmaceutical industry, disclosed a significant corporate action regarding the conversion of shares. Specifically, 337,000 A shares have now been converted into an equal number of B shares, a move that aligns with their Articles of Association.
The Details of the Conversion
According to regulatory standards, this conversion was officially recorded in the Trade Register. Post-conversion, the overall count of shares within Orion Corporation has reached 141,134,278. This innovative shift has adjusted the structure to include 31,971,783 A shares alongside 109,162,495 B shares.
Share Voting Power
Following this conversion process, the total number of votes associated with the company’s shares is now 748,598,155. This adjustment in voting power showcases the active management of shareholder interests and reinforces Orion's commitment to transparency with its investors.
Leadership Insights
Orion Corporation is led by experienced professionals, including Liisa Hurme, the President and CEO, and Mikko Kemppainen, the General Counsel. Their guidance is pivotal as the company navigates the complexities of share management and investor relations.
Contact for Investor Relations
For investors seeking more information about this transformation or the company's broader activities, Tuukka Hirvonen serves as the Head of Investor Relations. He can be reached at +358 10 426 2721, providing a direct line for inquiries.
About Orion Corporation
Orion Corporation has a rich history as a global Nordic pharmaceutical provider, dedicated to improving health and well-being for over a century. The company specializes in developing, manufacturing, and marketing a wide range of human and veterinary pharmaceuticals as well as active ingredients. Their extensive portfolio includes both proprietary and generic medicines, with an emphasis on consumer health products.
Core Areas of Expertise
Orion’s pioneering research and development efforts primarily focus on critical therapy areas, notably oncology and pain management. Proprietary products sourced from Orion are instrumental in treating various health conditions, including cancer, neurological disorders, and respiratory ailments.
Company Performance Overview
In terms of financial performance, Orion Corporation has demonstrated robust growth with net sales reaching EUR 1,542 million in the last fiscal year. This impressive figure reflects the dedication of their workforce, consisting of approximately 3,700 professionals around the globe, all working tirelessly to foster improved health outcomes.
Market Presence
Both A and B shares of Orion are publicly traded on Nasdaq Helsinki, allowing investors to participate in the company's growth journey. This access to the stock market represents an opportunity for ongoing investment and engagement in its strategic objectives.
Frequently Asked Questions
What does the share conversion entail?
The share conversion involves changing A shares into B shares, as per the company's Articles of Association.
Why is the share conversion important?
This conversion enhances share structure and voting power, reflecting corporate efficiency and shareholder transparency.
Who can I contact for more information?
For inquiries, you can reach Tuukka Hirvonen, the Head of Investor Relations, at +358 10 426 2721.
Where is Orion Corporation located?
Orion Corporation is headquartered at Orionintie 1A, FI-02200 Espoo, Finland.
What are Orion’s key market areas?
Orion specializes in oncology and pain management, producing both proprietary and generic pharmaceuticals.
